114 related articles for article (PubMed ID: 17074361)
21. Modeling oxaliplatin drug delivery to circadian rhythms in drug metabolism and host tolerance.
Clairambault J
Adv Drug Deliv Rev; 2007 Aug; 59(9-10):1054-68. PubMed ID: 17707544
[TBL] [Abstract][Full Text] [Related]
22. Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug.
Hamad I; Moghimi SM
Expert Opin Drug Deliv; 2008 Feb; 5(2):205-19. PubMed ID: 18248319
[TBL] [Abstract][Full Text] [Related]
23. Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy.
Moretti L; Yang ES; Kim KW; Lu B
Drug Resist Updat; 2007; 10(4-5):135-43. PubMed ID: 17627865
[TBL] [Abstract][Full Text] [Related]
24. Analysis of resonance chemotherapy in leukemia treatment via multi-staged population balance models.
Sherer E; Hannemann RE; Rundell A; Ramkrishna D
J Theor Biol; 2006 Jun; 240(4):648-61. PubMed ID: 16430925
[TBL] [Abstract][Full Text] [Related]
25. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
26. Mathematical modeling of cyclic treatments of chronic myeloid leukemia.
Komarova NL
Math Biosci Eng; 2011 Apr; 8(2):289-306. PubMed ID: 21631131
[TBL] [Abstract][Full Text] [Related]
27. Cell kinetics in a tumour cord.
Bertuzzi A; Gandolfi A
J Theor Biol; 2000 Jun; 204(4):587-99. PubMed ID: 10833358
[TBL] [Abstract][Full Text] [Related]
28. A minimal model of tumor growth inhibition.
Magni P; Germani M; De Nicolao G; Bianchini G; Simeoni M; Poggesi I; Rocchetti M
IEEE Trans Biomed Eng; 2008 Dec; 55(12):2683-90. PubMed ID: 19126447
[TBL] [Abstract][Full Text] [Related]
29. Towards whole-organ modelling of tumour growth.
Alarcón T; Byrne HM; Maini PK
Prog Biophys Mol Biol; 2004; 85(2-3):451-72. PubMed ID: 15142757
[TBL] [Abstract][Full Text] [Related]
30. A new classification system of anticancer drugs - based on cell biological mechanisms.
Wu XZ
Med Hypotheses; 2006; 66(5):883-7. PubMed ID: 16414204
[TBL] [Abstract][Full Text] [Related]
31. Antiangiogenics and radiotherapy.
Shannon AM; Williams KJ
J Pharm Pharmacol; 2008 Aug; 60(8):1029-36. PubMed ID: 18644195
[TBL] [Abstract][Full Text] [Related]
32. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
33. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
34. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
Liou JP; Hsu KS; Kuo CC; Chang CY; Chang JY
J Pharmacol Exp Ther; 2007 Oct; 323(1):398-405. PubMed ID: 17660383
[TBL] [Abstract][Full Text] [Related]
35. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
[TBL] [Abstract][Full Text] [Related]
36. Nanoparticles for delivery of chemotherapeutic agents to tumors.
Vijayaraghavalu S; Raghavan D; Labhasetwar V
Curr Opin Investig Drugs; 2007 Jun; 8(6):477-84. PubMed ID: 17621878
[TBL] [Abstract][Full Text] [Related]
37. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
38. Vascular remodelling of an arterio-venous blood vessel network during solid tumour growth.
Welter M; Bartha K; Rieger H
J Theor Biol; 2009 Aug; 259(3):405-22. PubMed ID: 19371750
[TBL] [Abstract][Full Text] [Related]
39. Stochastic modeling of cellular colonies with quiescence: an application to drug resistance in cancer.
Komarova NL; Wodarz D
Theor Popul Biol; 2007 Dec; 72(4):523-38. PubMed ID: 17915274
[TBL] [Abstract][Full Text] [Related]
40. Multi-anticancer drugs encapsulated in the micelle: a novel chemotherapy to cancer.
Liu P; Wang B; Weili Qiao JL
Med Hypotheses; 2008 Sep; 71(3):379-81. PubMed ID: 18556140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
